# HBV DNA is undetectable: why do I still need hepatitis B medicine? Understand why undetectable HBV DNA does not automatically mean treatment can stop, and what to ask your doctor. - URL: https://openhbv.com/articles/hbv-dna-undetectable-continue-treatment-en?locale=en - Language: en - Translation key: hbv-dna-undetectable-continue-treatment - Review status: source_backed - Last reviewed: 2026-10-14 - Audience: People with chronic hepatitis B and their families - Region: Global - Tags: Serology, Treatment, Monitoring After taking antiviral medicine for a while, you may feel relieved to see “HBV DNA not detected” on your report. A natural question follows: if the virus cannot be detected, can I stop treatment? **For someone receiving antiviral treatment for chronic hepatitis B, one undetectable HBV DNA result is not enough to decide that treatment can stop.** Other markers, liver health, and results over time also matter. [China chronic hepatitis B guideline, 2022](https://pmc.ncbi.nlm.nih.gov/articles/PMC12677433/) ## What does “not detected” mean? No viral DNA was detected in that blood sample; this does not prove that HBV has been completely eliminated. “Below the quantification limit” is different: a report saying “<15 IU/mL, detected” means viral DNA was found, but could not be measured accurately. Read the full report. [CDC laboratory guidance](https://www.cdc.gov/hepatitis/php/surveillance-guidance/hepatitis-b.html) ## Is undetectable DNA the same as losing surface antigen? HBV DNA measures circulating viral replication. Hepatitis B surface antigen, or HBsAg, is a separate marker: undetectable DNA does not automatically mean HBsAg has disappeared. Functional cure generally includes sustained HBsAg loss and undetectable HBV DNA after treatment ends. Viral genetic material may still remain in liver cells. Viral suppression, surface antigen loss, and complete viral elimination are different outcomes. [China guideline: definitions](https://pmc.ncbi.nlm.nih.gov/articles/PMC12677433/) ## Why continue taking medicine? Medicines such as entecavir and tenofovir suppress viral replication, slow cirrhosis progression, reduce liver cancer risk, and improve long-term survival. Better results can mean treatment is working. WHO notes that most people who start chronic hepatitis B treatment need to continue it for life. [WHO hepatitis B fact sheet](https://www.who.int/news-room/fact-sheets/detail/hepatitis-b) ## Can anyone stop treatment? Some carefully selected patients can. Guidelines differ; clinicians assess cirrhosis, HBeAg and HBsAg status, duration of viral suppression, and reliable follow-up. People with cirrhosis should be particularly cautious. Stopping can cause viral rebound, hepatitis flares, and sometimes liver decompensation. Any stopping plan must include monitoring and criteria for restarting treatment. [EASL 2025 hepatitis B guideline](https://www.hepb.org/assets/Uploads/EASL-guidelines-May-2025.pdf) ## Action checklist: what to ask at your next visit Continue your current prescription and bring previous reports. Ask your doctor: - Was HBV DNA not detected, or detected below the quantification limit? - What do my surface antigen, liver tests, and fibrosis assessment show? - Do I meet the criteria to discuss stopping treatment? - If I eventually stop, when will I have tests, and what would require restarting? An undetectable result is encouraging. Work with your doctor to maintain the benefit you have achieved. *This article provides education about oral antiviral treatment for chronic hepatitis B, not an individual instruction to stop medicine. Preventive treatment during pregnancy or immunosuppression requires a separate assessment.* ## References - [WHO Hepatitis B Fact Sheet](https://openhbv.com/sources/who-hepatitis-b-fact-sheet.md?locale=en) — World Health Organization - Original: https://www.who.int/news-room/fact-sheets/detail/hepatitis-b - Section: Treatment - Note: Supports the benefits of entecavir and tenofovir and the need for long-term treatment for most patients. - Quote: - Accessed: 2026-10-14 - [CDC Hepatitis B Surveillance Guidance](https://openhbv.com/sources/cdc-hepatitis-b-surveillance-guidance.md?locale=en) — Centers for Disease Control and Prevention - Original: https://www.cdc.gov/hepatitis/php/surveillance-guidance/hepatitis-b.html - Section: Interpreting Hepatitis B Laboratory Results - Note: Supports the distinction between undetectable HBV DNA and detectable DNA below the quantification limit; this surveillance source is not used to set treatment stopping criteria. - Quote: - Accessed: 2026-10-14 - [Guidelines for the Prevention and Treatment of Chronic Hepatitis B (version 2022)](https://openhbv.com/sources/guidelines-for-the-prevention-and-treatment-of-chronic-hepatitis-b-version-2022.md?locale=en) — Journal of Clinical and Translational Hepatology - Original: https://pmc.ncbi.nlm.nih.gov/articles/PMC12677433/ - Section: Definitions and nucleos(t)ide analogue treatment duration - Note: Supports functional cure terminology and the need to consider more than a single HBV DNA result before stopping treatment. - Quote: - Accessed: 2026-10-14 - [EASL 2025 Clinical Practice Guidelines on Hepatitis B](https://openhbv.com/sources/easl-2025-clinical-practice-guidelines-on-hepatitis-b.md?locale=en) — European Association for the Study of the Liver - Original: https://www.hepb.org/assets/Uploads/EASL-guidelines-May-2025.pdf - Section: Stopping nucleos(t)ide analogue therapy - Note: Supports clinician selection, close follow-up, retreatment planning, and the risks of relapse and decompensation after discontinuation. - Quote: - Accessed: 2026-10-14 This tool is for health education only and does not provide a personal diagnosis or treatment advice. Please consult a qualified doctor for individual medical decisions.